Please Wait

Applying Filters...

Drug Product Composition: bydureon

bydureon

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 USDMF

FINISHED DOSAGE FORMULATIONS

7 FDF Dossiers, 7 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS - 2MG/0.85ML (2MG/0.85ML), INJECTABLE;SUBCUTANEOUS - 300MCG/1.2ML (250MCG/ML), INJECTABLE;SUBCUTANEOUS - 600MCG/2.4ML (250MCG/ML), FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS - 2MG/VIAL

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 16 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

2 US Medicaid Prescriptions

PATENTS & EXCLUSIVITIES

251 US Patents, 8 US Exclusivities

REF. STANDARDS & IMPURITIES

1 Others

1 Others

Xls

Filters

Xls

USFDA APPLICATION NUMBER - 22200 / DOSAGE - FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS - 2MG/VIAL

Drug Product Composition: bydureon

Bydureon

bydureon

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers

2 USDMF

FINISHED DOSAGE FORMULATIONS

7 FDF Dossiers

7 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS - 2MG/0.85ML (2MG/0.85ML)

INJECTABLE;SUBCUTANEOUS - 300MCG/1.2ML (250MCG/ML)

INJECTABLE;SUBCUTANEOUS - 600MCG/2.4ML (250MCG/ML)

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS - 2MG/VIAL

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

16 NEWS #PharmaBuzz